Skip to content
Search

Latest Stories

UK-Indian business partnership makes vaccination roll out successful

WOCKHARDT UK, a subsidiary of India-based pharmaceutical and biotech company Wockhardt Ltd, has played a pivotal role in making the Covid-19 vaccination drive a big success in the UK.

The company’s Wrexham manufacturing facility in North Wales, which has been contracted by the UK government to manufacture the Oxford/AstraZeneca Covid-19 vaccine, was visited by the Indian High Commissioner Gaitri Issar Kumar on Monday (26).


The visit was part of a tour of Indian backed or supported businesses in the UK.

As part of her visit, the High Commissioner was provided with a tour of the state-of-the-art vaccine fill finish facility which until August 2022 is reserved for manufacturing vaccines.

“The United Kingdom’s vaccination programme has been a beacon for the world in many ways.  It is a matter of great satisfaction that an India-UK collaboration in vaccine manufacture here in the UK has played a vital part in the roll out.  The contribution of Wockhardt at Wrexham is one of the best examples of the success and significant potential of India-UK partnerships in the healthcare sector,” she said.

Kumar was joined by the Indian Honorary Consul for Wales, Raj Aggarwal OBE, RNR.

Wockhardt Managing Director and Chief Executive Officer Dr Murtaza Khorakiwala, said, “We are honoured to have a visit from the high commissioner of India to recognise our India-UK collaboration and essential role in mitigating the global impact of Covid-19.”

The pandemic has posed a big challenge for all and it needed a combined effort to overcome, said Dr Habil Khorakiwala, Founder Chairman of Wockhardt.

Ravi Limaye, Managing Director of Wockhardt UK said, “It is an honour to share our pride in the delivery of the vaccine programme to the High Commissioner, Gaitri Issar Kumar today (26), and to demonstrate the impact that Indian-led pharmaceutical innovation is having in the global fight against the Covid-19 pandemic.”

Kumar’s visit is the latest one in a series of high-profile attendances at the Wockhardt UK site.

Earlier, HRH Prince Charles and the UK prime minister Boris Johnson have also visited Wockhardt UK to witness the fill finish production of the vaccines.

With presence in the US, the UK, Ireland, Switzerland, France, Mexico, Russia and many other countries, Wockhardt employs over 5,000 people and 27 nationalities.

More For You

Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less
NICE approves once-daily tablet Linzagolix for endometriosis

NICE recommends Linzagolix with add-back therapy for endometriosis

Image credit: Getty Images

NICE approves new at-home treatment for endometriosis

The National Institute for Health and Care Excellence (NICE) has recommended Linzagolix (brand name Yselty), a once-daily tablet, as a new treatment option for endometriosis.

Developed by Theramex, Linzagolix is approved for use alongside hormonal add-back therapy in adults of reproductive age who have previously tried other medical or surgical treatments for the condition.

Keep ReadingShow less